The FDA has approved Furoscix (furosemide injection) a loop diuretic used for the at- home treatment of adults with congestion due to fluid overload in chronic heart failure.

scPharmaceuticals Inc., focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced that the U.S. Food and Drug Administration (FDA) has approved Furoscix (furosemide injection), a proprietary formulation of furosemide delivered via an on-body infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.

Furoscix demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide. Furoscix is not indicated for emergency situations or in patients with acute pulmonary edema. The Furoscix infusion will last about 5 hours. Furoscix Infusor will deliver only an 80- mg dose. Furoscix is the first and only FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home via the Furoscix Infusor.